Consistent with our findings, S100A9 plays a critical role in both NAFLD and COPD, underscoring its potential as a key target for developing diagnostic and therapeutic strategies for NASH in COPD patients. The gene discussed is S100A9; the disease is metabolic dysfunction-associated steatotic liver disease.